Multiple Myeloma

Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.

Intervention in early or "smoldering" myeloma with a three-drug regimen led to complete responses in a group of high-risk patients, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.

A higher cumulative dose of bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve OS in patients with previously untreated multiple myeloma.

Several protocols of novel immune and targeted agents show promise alone and in combination, including monoclonal antibodies, immune therapies, and newer proteasome inhibitors.

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for stem cell transplantation.

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Researchers highlighted the latest developments in the treatment of multiple myeloma at the 2013 ASCO Annual Meeting. Noteworthy abstracts included updated data on pomalidomide, as well as research involving the novel agents daratumumab and elotuzumab.

In an interview with OncologyLive, Brian G.M. Durie, MD, provided details about the Black Swan initiative and how he expects the project to develop.

Patients with previously treated multiple myeloma responded well to therapy with the monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone, with a high objective response rate and longer progression-free survival.

As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn't save who have most affected his path.

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with multiple myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.

There have been waves of advancements in the treatment of multiple myeloma and further exploration of existing regimens and research into novel therapeutics hold the promise of advances.

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, comments on new potential targets in myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.

Working in the laboratory and the clinic, Shaji K. Kumar, MD, has made a discovery: that there aren't enough hours in a day.

Shaji K. Kumar, MD, is working to understand the genomic intricacies of multiple myeloma, particularly the role played by activity associated with the TP53 gene.

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancies.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

The FDA announced the approval of pomalidomide for the treatment of multiple myeloma after patients have relapsed or become refractory to other cancer drugs.

James R. Berenson, MD, discusses a phase I/II study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma.